Based on these results, we conclude that CDK4/6 inhibitors may regulate CDK6 degradation via the AMBRA1‐CUL4A complex and negatively impact lysosomal function via TFEB and TFE3, followed by impaired autophagy and SCLC cell death (Figure 7F). The gene discussed is CDK4; the disease is small cell lung carcinoma.